drugset / Trial / NCT00674791
Study of Cancer Peptides Vaccine Plus GM-CSF as Adjuvant Treatment for High Risk (TXN2-3M0) or Metastatic Breast Cancer With No Evidence of Disease
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This study will evaluate the safety and feasibility of administering a peptide vaccine consisting of twelve different tumor-rejection antigens to patients with high risk (TxN2-3M0) or metastatic breast cancer with no evidence of disease following their completion of systemic therapy. The vaccine is designed to elicit immune responses against twelve different pathways that are essential to tumor growth, survival and metastasis.
Timeline
- Start
- 2007-06
- Primary completion
- 2010-01
- Completion
- 2010-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | OCPM Immunotherapeutic Vaccine | Vaccine | 0.1 mg | Subcutaneous |
| Subject | OCPM Immunotherapeutic Vaccine | Vaccine | 1 mg | Subcutaneous |